Chart-Typ:
Zeitraum:
| Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen |
| Cardiol Therapeutics Inc.: Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program | Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia... ► Artikel lesen |
| Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.04.2026 / 15:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen |
| XFRA CAPITAL ADJUSTMENT INFORMATION - 28.05.2026 | Das Instrument JGNR IE0005FKEK99 JPM-GSS BD UE A ETF wird cum Kapitalmassnahme gehandelt am 28.05.2026 und ex Kapitalmassnahme am 29.05.2026 The instrument JGNR IE0005FKEK99 JPM-GSS BD UE A ETF is traded... ► Artikel lesen |
| BTCS, Inc.: BTCS Reports Gross Profit of $1.0 Million and 47% Gross Margin for First Quarter 2026 | WAYNE, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, a company focused on blockchain infrastructure... ► Artikel lesen |
| BTCS, Inc.: BTCS Reports 305% Year-Over-Year Revenue Growth to Record $16.5 Million for Full Year 2025 | WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, a company focused on blockchain infrastructure... ► Artikel lesen |
| MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF | Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company... ► Artikel lesen |
| MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes | Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care... ► Artikel lesen |
| MannKind Reports First Quarter 2026 Financial Results and Provides Business Update | Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTCHAINS GROUP LTD ADR finden Sie auf Wallstreet Online.